LOXL2: A potential therapeutic target in the treatment of hepatocellular carcinoma?

Dig Liver Dis

Department of Geriatric Medicine, Chinese PLA 88 Hospital, Tai(')an 271000, China. Electronic address:

Published: September 2023

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2023.04.004DOI Listing

Publication Analysis

Top Keywords

loxl2 potential
4
potential therapeutic
4
therapeutic target
4
target treatment
4
treatment hepatocellular
4
hepatocellular carcinoma?
4
loxl2
1
therapeutic
1
target
1
treatment
1

Similar Publications

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its aggressive nature and dismal prognosis, largely attributed to its unique tumor microenvironment. However, the molecular mechanisms by which tumor-associated macrophages (TAMs) promote PDAC progression, particularly the role of β-catenin signaling in regulating TAM phenotype and function, remain incompletely understood. Initially, we performed comprehensive analyses of RNA-seq and single-cell RNA-seq (scRNA-seq) datasets to investigate OSM and LOXL2 expression patterns in PDAC.

View Article and Find Full Text PDF

Hyperglycemia Inhibits AAA Expansion: Examining the Role of Lysyl Oxidase.

Am J Physiol Heart Circ Physiol

December 2024

B. Timothy Baxter, MD: University of Nebraska Medical Center, 68198 Nebraska Medicine, Omaha, Ne 68198-2500 (402-639-0144).

Abdominal aortic aneurysm (AAA) is a common, progressive and potentially fatal dilation of the most distal aortic segment. Multiple studies with longitudinal follow-up of AAA have identified markedly slower progression among patients affected with diabetes. Understanding the molecular pathway responsible for the growth inhibition could have implications for therapy in nondiabetic AAA patients.

View Article and Find Full Text PDF

O-GlcNAcylation stabilized WTAP promotes GBM malignant progression in an N6-methyladenosine-dependent manner.

Neuro Oncol

December 2024

Department of Neurosurgery, Qilu Hospital of Shandong University, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan 250012, Shandong, China.

Background: Interactions between mesenchymal glioblastoma stem cells (MES GSCs) and myeloid-derived macrophages (MDMs) shape the tumor-immunosuppressive microenvironment (TIME), promoting the progression of glioblastoma (GBM). N6-methyladenosine (m6A) plays important roles in the tumor progression. However, the mechanism of m6A in shaping the TIME of GBM remains elusive.

View Article and Find Full Text PDF

Prognostic significance of LOXL2 enzyme activity in primary myelofibrosis.

Medicine (Baltimore)

December 2024

School of Medicine, Pingdingshan University, Pingdingshan, China.

Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, but the underlying molecular mechanisms remain incompletely understood. Here, we investigated the role of lysyl oxidase-like 2 (LOXL2), an enzyme involved in extracellular matrix remodeling, in PMF pathogenesis. Analysis of bone marrow cells from PMF patients revealed significantly elevated LOXL2 mRNA expression compared to healthy controls, which was further validated using 2 independent Gene Expression Omnibus datasets (GSE26049 and GSE12234).

View Article and Find Full Text PDF
Article Synopsis
  • Researchers investigated how oxidative stress response-related genes (OSRGs) impact lung adenocarcinoma (LUAD) to create a genetic signature that could predict patient prognosis and suggest treatment options.
  • They developed a risk prediction model using clinical data and various assay methods to analyze the relationship between gene expression and factors like immune cell infiltration and chemotherapy sensitivity.
  • The study concluded that the identified gene signature could serve as a reliable biomarker for predicting patient outcomes and therapy responses in LUAD, with specific findings on the effects of DKK1 on cell behavior.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!